Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP in patients with recurrent genital herpes infections
2019-001572-11Phase 4Terminated
- Sponsor
- Labo'Life
- Start
- Jul 2020
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in genital herpes and herpes infections comparing 2LHERP with Placebo (2 arms). Primary endpoint: Change in number of genital herpes episodes at 12 months. Started Jul 2020; status: terminated.
02
Drugs
2LHERP
03
Conditions
genital herpesherpes infections
Beyond the preview
Go deeper on 2019-001572-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001572-11.